[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Piazza CD, Sampaio SA: [Remission of extensive lentigo maligna after treatment with imiquimod]. An Bras Dermatol; 2009 Jan-Feb;84(1):82-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remission of extensive lentigo maligna after treatment with imiquimod].
  • Lentigno maligna is a melanoma in situ that most commonly appears on areas exposed to ultraviolet radiation, in elderly patients.
  • Treatment is required mainly to minimize the risk of progression to lentigo maligna melanoma.
  • The present report refers to an elderly patient with recurrent lesions of lentigo maligna in her face, who was successfully treated with topical imiquimod, which showed to be a useful therapy for some cases of the disease.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19377765.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


2. Demirci H, Shields CL, Bianciotto CG, Shields JA: Topical imiquimod for periocular lentigo maligna. Ophthalmology; 2010 Dec;117(12):2424-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod for periocular lentigo maligna.
  • PURPOSE: To evaluate the efficacy of topical imiquimod 5%, a local immune response modifier, in the treatment of periocular lentigo maligna.
  • PARTICIPANTS: Five consecutive patients with biopsy-proven periocular lentigo maligna.
  • METHODS: Periocular lentigo maligna was treated with topical imiquimod 5%.
  • The clinical features, treatment schedule, response to treatment, and complications were analyzed retrospectively.
  • MAIN OUTCOME MEASURES: Response to treatment and complications.
  • The anatomic location of lentigo maligna was the medial canthal area in 2 patients, the lateral canthal area in 1 patient, and the lower eyelid in 2 patients.
  • The medication was placed only on the skin and not the globe.
  • The mean duration of treatment was 9 months (range, 1-14 months).
  • Lentigo maligna partially resolved in 3 patients and completely resolved in 2 patients.
  • Treatment was discontinued in 2 patients (one temporarily and the other permanently) because of intolerable local side effects of discomfort, redness, swelling, and cutaneous excoriation.
  • There was no recurrence of lentigo maligna in those with complete or partial response (mean follow-up, 20 months).
  • CONCLUSIONS: Periocular lentigo maligna seems to respond to topical imiquimod 5% treatment.
  • Topical imiquimod 5% treatment for periocular lentigo melanoma deserves further study.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Eyelid Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy


3. Bourguignon R, Paquet P, Quatresooz P, Piérard GE: [How I treat ... lentigo maligna by topical imiquimod]. Rev Med Liege; 2005 Sep;60(9):691-4
ORBi (University of Liege). Free full Text at ORBi .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [How I treat ... lentigo maligna by topical imiquimod].
  • [Transliterated title] Comment je traite ... un lentigo malin par l'imiquimod topique (Aldara).
  • Lentigo maligna is a special form of in situ cutaneous melanoma that develops on the face of sun worshipers.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16265961.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


Advertisement
4. Martín T, Ojeda A, Martínez S, Vera A: [Lentigo maligna treated with 5% imiquimod cream]. Actas Dermosifiliogr; 2005 Dec;96(10):700-2
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lentigo maligna treated with 5% imiquimod cream].
  • [Transliterated title] Lentigo maligno tratado con crema de imiquimod al 5%
  • Lentigo maligna (LM) is considered to be an in-situ stage of lentigo maligna melanoma.
  • 30% to 35% of untreated lentigo malignas can progress into lentigo maligna melanoma.
  • The treatment of choice for this pathology is surgical excision with margins of 0.5 cm. of clinically normal skin around the lesion, or Mohs microsurgery.
  • We present the case of a patient with LM, treated with 5% imiquimod cream, with an excellent therapeutic response.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476324.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Dosage Forms; 99011-02-6 / imiquimod
  •  go-up   go-down


5. Naylor MF, Crowson N, Kuwahara R, Teague K, Garcia C, Mackinnis C, Haque R, Odom C, Jankey C, Cornelison RL: Treatment of lentigo maligna with topical imiquimod. Br J Dermatol; 2003 Nov;149 Suppl 66:66-70
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lentigo maligna with topical imiquimod.
  • A published case report and anecdotal experience suggested that topical imiquimod is an effective treatment for stage 0 melanoma (lentigo maligna).
  • To gauge the efficacy of this therapy, we undertook a trial of topical imiquimod in 30 subjects with histologically confirmed lentigo maligna.
  • Thirty subjects with lentigo maligna were recruited for an open-labelled efficacy trial with daily topical application of imiquimod 5% cream for 3 months.
  • In order to determine an initial response rate, a four-quadrant biopsy was carried out on all patients 1 month after cessation of treatment, targeting the most clinically and dermatoscopically suspicious areas.
  • Of 28 evaluable subjects who have completed the 3-month treatment phase, 26 (93%) were complete responders and two were treatment failures at the time of the 4-quadrant biopsy.
  • Over 80% of the 28 subjects that completed treatment have been followed for more than 1 year with no relapses.
  • The results of this study demonstrate that topical imiquimod produces a high complete response rate in lentigo maligna when applied daily for 3 months.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy
  • [MeSH-minor] Administration, Topical. Cytokines / adverse effects. Drug Administration Schedule. Erythema / chemically induced. Female. Follow-Up Studies. Humans. Male. Ointments. Skin Ulcer / chemically induced. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616356.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Cytokines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


6. Powell AM, Russell-Jones R: Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy. J Am Acad Dermatol; 2004 May;50(5):792-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
  • Clinically amelanotic lentigo maligna often resembles an inflammatory lesion rather than a melanoma in situ.
  • We present two cases of extensive amelanotic lentigo maligna presenting as gradually enlarging erythematous patches on the faces of women following incomplete excisions of lentigo maligna.
  • Because of their site and size, therapeutic options were limited; the lesions have, however, resolved (clinically and histologically) following the topical application of 5% imiquimod cream.
  • We discuss the rationale for the use of imiquimod in the treatment of lentigo maligna.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15097969.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


7. Vereecken P, Heenen M: Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%. Int J Clin Pract; 2002 Jan-Feb;56(1):68-9
Hazardous Substances Data Bank. 1,7-HEPTANEDICARBOXYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent lentigo maligna melanoma: regression associated with local azelaic acid 20%.
  • The efficacy of azelaic acid in the treatment of lentigo maligna and melanoma has already been described and this local treatment is considered by some as an alternative agent when other forms of therapy are not realisable.
  • Here we report a case of a patient with local recurrence of a stage IV lentigo maligna melanoma of the cheek which cleared after treatment with azelaic acid cream 20%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Dermatologic Agents / therapeutic use. Dicarboxylic Acids / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11831841.001).
  • [ISSN] 1368-5031
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Dermatologic Agents; 0 / Dicarboxylic Acids; F2VW3D43YT / azelaic acid
  •  go-up   go-down


8. Micali G, Lacarrubba F, Nardone B, Nasca MR: Videodermatoscopy of lentigo maligna treated with imiquimod. J Drugs Dermatol; 2008 Nov;7(11):1077-80
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Videodermatoscopy of lentigo maligna treated with imiquimod.
  • Lentigo maligna (LM) is an in situ variant of cutaneous melanoma, which usually occurs in sun-damaged skin.
  • Surgical treatment of LM is often difficult and not well accepted by patients, as lesions are usually quite large and located on the face.
  • The authors report of 2 female patients with LM on the nose (aged 39 and 48 years) treated with imiquimod 5% cream applied 5 times a week for a total duration of 4 months.
  • Videodermatoscopy, a noninvasive diagnostic technique, was used to address the diagnosis and to monitor treatment response with imiquimod therapy and during follow-up.
  • At the end of the treatment period, the lesions had cleared in both patients, with no evident remnants confirmed by videodermatoscopy.
  • The authors' experience, in agreement with other clinical reports and open trials, suggests that topical imiquimod is a valuable treatment option capable of leading LM to clinical clearance.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Dermoscopy. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110742.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


9. Göhl J, Hohenberger W, Merkel S: [Malignant melanoma]. Chirurg; 2009 Jun;80(6):559-67
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant melanoma].
  • [Transliterated title] Malignes Melanom.
  • There are four histological types: superficial spreading melanoma, nodular melanoma, acrolentiginous melanoma and lentigo maligna melanoma.
  • In the case of lymph node metastases therapeutic dissection is recommended, in patients with in-transit metastases of the extremities hyperthermic isolated limb perfusion with cytostatic agents may be indicated.
  • Adjuvant, neoadjuvant and palliative procedures, such as radiotherapy, chemotherapy and immunotherapy are additional treatment options.
  • [MeSH-major] Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Prognosis. Skin / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):119-26 [12925966.001]
  • [Cites] Cancer Invest. 2008 Jun;26(5):516-34 [18568775.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1983-91 [11064356.001]
  • [Cites] Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):280-90 [11586069.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3445-55 [18612161.001]
  • [Cites] J Exp Med. 2002 May 20;195(10):1279-88 [12021308.001]
  • [Cites] J Am Acad Dermatol. 2007 Oct;57(4):659-64 [17870430.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2370-80 [11331315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):607-18 [10348291.001]
  • [Cites] Dermatol Surg. 2003 Apr;29(4):366-74 [12656815.001]
  • (PMID = 19444395.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Rajpar SF, Marsden JR: Imiquimod in the treatment of lentigo maligna. Br J Dermatol; 2006 Oct;155(4):653-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod in the treatment of lentigo maligna.
  • BACKGROUND: Lentigo maligna (LM) is treated to prevent progression to lentigo maligna melanoma (LMM).
  • Surgery remains the treatment of choice, although topical immunotherapy with imiquimod has recently become a popular alternative.
  • OBJECTIVES: In this review, we have analysed the published literature relating to the use of imiquimod for LM, in order to understand better the utility of this treatment.
  • RESULTS: Eleven case reports and four open-label studies were identified, comprising a total of 67 patients who completed treatment with imiquimod for LM.
  • There was significant variability in treatment schedules and regimens.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Humans. Interferon Inducers / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16965411.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  • [Number-of-references] 33
  •  go-up   go-down


11. Powell AM, Russell-Jones R, Barlow RJ: Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol; 2004 Jan;29(1):15-21
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod immunotherapy in the management of lentigo maligna.
  • Melanoma in situ of the lentigo maligna (LM) type is a precursor lesion of LM melanoma.
  • This study describes the use of imiquimod 5% cream as topical immunotherapy in the management of lentigo maligna.
  • Twelve patients (average age 63 years, 10 female), of biopsy-proven facial LM were treated with topical imiquimod, three times a week for 6 weeks.
  • In the absence of an inflammatory response, patients were asked to apply the treatment daily.
  • Two of these also developed secondary infection.
  • Imiquimod 5% cream appears to offer a potential noninvasive method for the treatment of lentigo maligna.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Immunotherapy / methods. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14723712.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


12. Wolf IH, Cerroni L, Kodama K, Kerl H: Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol; 2005 Apr;141(4):510-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
  • BACKGROUND: Surgical excision is the treatment of choice for lentigo maligna (LM), or melanoma in situ.
  • Topical application of imiquimod, a local immune response modifier, is a novel therapeutic approach that leads to LM tumor clearance.
  • OBSERVATIONS: Six biopsy-proven cases of LM from 5 patients (age range, 67-80 years) in whom standard surgical therapy was contraindicated were enrolled in the study.
  • Time to complete clearing varied from 5 to 13 weeks based on both clinical and histopathologic findings.
  • The inflammatory infiltrate following imiquimod treatment consisted of T-helper lymphocytes mixed with a significant number of cytotoxic cells and monocytes or macrophages.
  • In all patients, erythema and erosions occurred at the treated area 2 to 4 weeks after initiation of imiquimod therapy.
  • CONCLUSIONS: Topical imiquimod appears to be an excellent therapeutic option for LM.
  • Imiquimod can be added to the list of therapeutic approaches for carefully selected patients with LM.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Pilot Projects. Risk Assessment. Single-Blind Method. Treatment Outcome

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Dermatol. 2006 Apr;142(4):530-1 [16618884.001]
  • (PMID = 15837872.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


13. Spenny ML, Walford J, Werchniak AE, Beltrani V, Brennick JB, Storm CA, Perry AE, Chapman MS: Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis; 2007 Feb;79(2):149-52
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports.
  • Lentigo maligna (LM) is an in situ variant of melanoma.
  • We evaluated the treatment course of topical imiquimod in 12 patients with LM.
  • Most patients chose imiquimod cream as their initial form of treatment; however, other patients had a history of LM recurrence after excision or had positive histologic margins at the time of excision.
  • Initial application regimens varied from 2 to 7 times weekly.
  • The average duration of treatment was 15.7 weeks but ranged from 7 to 44 weeks.
  • These findings suggest that imiquimod cream 5% may be an effective alternative treatment for LM.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Ointments. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17388218.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ointments; 99011-02-6 / imiquimod
  •  go-up   go-down


14. Michalopoulos P, Yawalkar N, Brönnimann M, Kappeler A, Braathen LR: Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod. Br J Dermatol; 2004 Oct;151(4):903-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod.
  • Lentigo maligna (LM) is an in situ melanoma which usually occurs in sun-damaged skin on the head and neck of elderly patients.
  • Depending on the anatomical site and its size treatment of LM can be problematic and usually includes surgical excision or radiotherapy.
  • Recent reports indicate that topical imiquimod may be an effective treatment.
  • However, no data on the underlying immune response in the skin during treatment of LM with topical imiquimod are available so far.
  • Skin biopsy specimens were obtained before, during (at week 10) and 4 weeks after cessation of topical treatment with imiquimod 5% cream.
  • A complete clinical and histological clearance of the skin lesion was achieved, with no recurrence up to 9 months after the end of treatment.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy. T-Lymphocyte Subsets / drug effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15491436.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


15. Ahmed I, Berth-Jones J: Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol; 2000 Oct;143(4):843-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod: a novel treatment for lentigo maligna.
  • Lentigo maligna is the in situ phase of lentigo maligna melanoma, and if left untreated it may progress to invasive melanoma.
  • Conventional surgery using a 5-10 mm margin is the recommended treatment; however, lesions can be quite large and surgical removal may involve extensive plastic repair.
  • We report an elderly patient with a large lentigo maligna on the scalp who was reluctant to have surgery.
  • We tried topical imiquimod 5% cream (Aldara), a local immunomodulator, which has recently become available for the treatment of external genital and perianal warts.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Interferon Inducers / therapeutic use. Scalp. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11069469.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon Inducers; 99011-02-6 / imiquimod
  •  go-up   go-down


16. Hopson B, Richey D, Sajben FP: Treatment of lentigo maligna with imiquimod 5% cream. J Drugs Dermatol; 2007 Oct;6(10):1037-40
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lentigo maligna with imiquimod 5% cream.
  • Lentigo maligna (LM) is an in situ melanoma that occurs in sun-damaged skin on the head and neck of elderly patients.
  • Surgical excision is the treatment of choice for LM.
  • Histologic clearance of the lentigo maligna was evident in skin biopsies.
  • Imiquimod 5% cream appears effective in the treatment of lentigo maligna.
  • We describe the treatment of a patient with facial LM with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17966182.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


17. Little JW: Melanoma: etiology, treatment, and dental implications. Gen Dent; 2006 Jan-Feb;54(1):61-66; quiz, 67
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma: etiology, treatment, and dental implications.
  • Melanoma is one of the most serious skin cancers.
  • Melanoma also can arise from melanocytes located in other regions of the body such as the eye, meninges, digestive tract, mucosal surfaces, or lymph nodes.
  • There are no proven causes of melanoma but the most commonly associated factor is episodic exposure to the sun.
  • Melanoma is a common cancer that has been increasing in incidence for the last 35 years.
  • The median age at the time of diagnosis is 53 years.
  • Five-year survival rates for melanoma of the skin have been increasing since 1976.
  • There are four types of melanoma: superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lintiginous melanoma.
  • Clinical signs indicating possible melanoma are asymmetry, border irregularity, color variation, increase in diameter, elevation, ulceration, and bleeding of pigmented lesions.
  • Treatment consists of surgical excision, lymph node dissection, limb perfusion, regional chemotherapy infusion, radiation, intralesional immunotherapy, systemic chemotherapy, and/or interferon-alpha, depending on the staging of the melanoma.
  • Lesions suspected of melanoma must be biopsied, which usually involves referral of the patient.
  • [MeSH-major] Head and Neck Neoplasms. Melanoma. Mouth Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494125.001).
  • [ISSN] 0363-6771
  • [Journal-full-title] General dentistry
  • [ISO-abbreviation] Gen Dent
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 44
  •  go-up   go-down


18. Powell AM, Robson AM, Russell-Jones R, Barlow RJ: Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. Br J Dermatol; 2009 May;160(5):994-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up.
  • BACKGROUND: Melanoma in situ/lentigo maligna (LM) is a potential precursor of LM melanoma.
  • Although surgical excision is the treatment of choice, this may not be desirable or feasible for large lesions at functionally or cosmetically important sites.
  • There were 37 responders and 11 treatment failures (of whom two were 'partial responders').
  • One patient in whom treatment failed subsequently developed invasive disease.
  • However, the ability to develop an inflammatory reaction to imiquimod was a strong predictor of therapeutic benefit.
  • CONCLUSIONS: We consider imiquimod to have a role in the treatment of LM in patients in whom surgery may be contraindicated or for those in whom the cosmetic or functional consequences may be considerable.
  • Until better characterized, its use should probably be confined to centres with experience in the detection and treatment of LM and melanoma.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222462.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


19. Bogenrieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W: Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology; 2002;205(2):174-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
  • Induction of multiple eruptive dermal and atypical melanocytic naevi has frequently been reported in children with malignant haematological diseases and chemotherapy-induced immunosuppression.
  • This is the first report of an adult patient to develop multiple eruptive melanocytic skin lesions while undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Carcinoma / drug therapy. Carcinoma / secondary. Colorectal Neoplasms / pathology. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hutchinson's Melanotic Freckle / chemically induced. Prodrugs / adverse effects. Skin Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Capecitabine. Fluorouracil. Humans. Male. Melanoma / physiopathology. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / pathology. Nevus, Pigmented / chemically induced. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12218237.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


20. Fleming CJ, Bryden AM, Evans A, Dawe RS, Ibbotson SH: A pilot study of treatment of lentigo maligna with 5% imiquimod cream. Br J Dermatol; 2004 Aug;151(2):485-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of treatment of lentigo maligna with 5% imiquimod cream.
  • BACKGROUND: Lentigo maligna (LM) is an in situ form of malignant melanoma, and surgical excision is often unsatisfactory.
  • Imiquimod cream is an immune response modifier and induces a predominantly T-helper 1 type response.
  • OBJECTIVES: Assessment of histological and clinical response of surgically resectable LM after treatment with 5% imiquimod cream.
  • RESULTS: Complete or almost complete clearance of pigmentation with minimal residual histological evidence of LM was observed in four patients, one patient showed no clinical or histological improvement, and the remaining patient had almost no residual pigmentation clinically after treatment yet histopathological changes remained as severe as before treatment.
  • CONCLUSIONS: Topical imiquimod cream merits further investigation as a new therapy for LM.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Humans. Middle Aged. Pilot Projects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15327559.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


21. Lang PG: Current concepts in the management of patients with melanoma. Am J Clin Dermatol; 2002;3(6):401-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of patients with melanoma.
  • Melanoma is a significant health problem.
  • Despite public education and free cancer screenings, the incidence and mortality of melanoma continues to rise; however, many currently diagnosed melanomas are thin lesions, suggesting that education and awareness is having an impact.
  • Although large congenital nevi may be precursors of melanoma, small and medium congenital nevi have an insignificant risk for melanoma development.
  • Large congenital nevi, which are axial in location, appear to be more likely to develop melanoma and are associated with melanocytosis and melanoma of the CNS, both of which portend a poor prognosis.
  • Lymphoscintigraphy and sentinel node biopsy have replaced elective node dissections, thus decreasing the morbidity associated with the surgical management of melanoma.
  • For example, cryosurgery or radiation therapy may be indicated in the frail, elderly individual with a large facial lentigo maligna.
  • Mohs surgery is the treatment of choice for head and neck melanomas and those located in areas where maximum preservation of tissue is required and for desmoplastic and acral lentiginous melanomas.
  • Much more work remains in the area of adjuvant therapy, chemotherapy, and immunotherapy.
  • Dacarbazine remains the drug of choice in disseminated melanoma, but remissions are usually short lived.
  • Although high dose interferon increases disease-free and overall survival in some patients, it remains a controversial drug which is not easily tolerated.
  • In the new staging system for melanoma, ulceration is second only to Breslow's thickness.
  • Except for lesions <1mm thick, the Clark's level of invasion has been de-emphasized.
  • [MeSH-major] Melanoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Humans. Incidence. Interferon-alpha / therapeutic use. Lymph Node Excision. Male. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / therapy. Prognosis. Recombinant Proteins. Risk Factors

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12113649.001).
  • [ISSN] 1175-0561
  • [Journal-full-title] American journal of clinical dermatology
  • [ISO-abbreviation] Am J Clin Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  • [Number-of-references] 285
  •  go-up   go-down


22. Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH: Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B; 2008 May 29;91(2-3):67-76
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells.
  • Although photodynamic mechanisms (i.e. through endogenous photosensitizers) play a role in UVA phototherapy for the treatment of skin disorders such as eczema and psoriasis, photodynamic therapy employing exogenous photosensitizers are currently being used only for the treatment of certain forms of non-melanoma skin cancers and actinic keratoses.
  • We show that an exposure to 1 microM UVA-activated hypericin does not bring about cell death, while 3 microM activated hypericin induces a necrotic mode of cell death in pigmented melanoma cells and melanocytes and an apoptotic mode of cell death in non-pigmented melanoma cells and keratinocytes.
  • In contrast, this study shows that cells that do not contain melanosomes (non-pigmented melanoma cells and keratinocytes) die by apoptosis.
  • This work suggests that UVA is effective in activating hypericin and that this phototoxicity may be considered as treatment option in some cases of lentigo maligna or lentigo maligna melanoma that are too large for surgical resection.
  • [MeSH-major] Keratinocytes / drug effects. Melanocytes / drug effects. Melanoma / pathology. Perylene / analogs & derivatives. Photochemotherapy / methods. Photosensitizing Agents / toxicity. Skin / cytology
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / metabolism. Caspase 7 / metabolism. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Humans. Intracellular Space / metabolism. Necrosis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342534.001).
  • [ISSN] 1011-1344
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7
  •  go-up   go-down


23. Muñoz CM, Sánchez JL, Martín-García RF: Successful treatment of persistent melanoma in situ with 5% imiquimod cream. Dermatol Surg; 2004 Dec;30(12 Pt 2):1543-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
  • BACKGROUND: Five percent imiquimod cream, a topically applied immune response modifier with potent antiviral and antitumor activity, has been reported to be effective in the management of lentigo maligna and cutaneous metastases from melanoma.
  • OBJECTIVE: We report a case in which 5% imiquimod cream was effective in the management of a persistent melanoma in situ.
  • METHODS: Five percent imiquimod cream was applied to the affected area twice to three times a week, as tolerated.
  • RESULTS: After 4 months of treatment, repeated biopsies of the previously affected areas showed complete regression of the melanoma.
  • CONCLUSION: Treatment of melanoma in situ of sun-damaged areas with 5% imiquimod cream certainly appears warranted in selected cases where surgical procedures have failed or are not feasible owing to factors such as size and/or localization of the lesion, advanced age, or deteriorated medical status of the patient.
  • Rigorous posttreatment follow-up is mandatory, because long-term recurrence rates after treatment of melanoma in situ with imiquimod are yet unknown.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Drug Administration Schedule. Female. Humans. Neck

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606836.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


24. Basarab T, Millard TP, McGregor JM, Barker JN: Atypical pigmented lesions following extensive PUVA therapy. Clin Exp Dermatol; 2000 Mar;25(2):135-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pigmented lesions following extensive PUVA therapy.
  • We report a 38-year-old woman with psoriasis who developed multiple atypical lentigines following psoralen photochemotherapy (PUVA).
  • The lentigines first appeared 12 years ago, 3 years after she commenced intermittent PUVA treatment.
  • Histology of a representative lesion was consistent with a PUVA lentigo and no atypical melanocytes were seen.
  • At present, a link between malignant melanoma and PUVA lentigines has not been established.
  • [MeSH-major] Lentigo / etiology. PUVA Therapy / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Psoriasis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2001 Jul;26(5):459 [11488842.001]
  • (PMID = 10733639.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


25. Wenzel J, Tormo D, Tüting T: Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects. Handb Exp Pharmacol; 2008;(183):201-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toll-like receptor-agonists in the treatment of skin cancer: history, current developments and future prospects.
  • Subsequently, the use of synthetic DNA, synthetic RNA and synthetic small immunostimulatory molecules for immunotherapy of early forms of epithelial carcinoma (actinic keratoses) and melanoma (lentigo maligna), as well as for advanced metastatic melanoma, is comprehensively presented.
  • Finally, current developments and future prospects for immunotherapy of occult or unresectable melanoma metastastases, the most important clinical problem today, are discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Skin Neoplasms / drug therapy. Toll-Like Receptors / agonists
  • [MeSH-minor] Adjuvants, Immunologic / therapeutic use. Animals. DNA / therapeutic use. Humans. Immunotherapy. Oligonucleotides / therapeutic use. RNA / therapeutic use. Skin / cytology. Skin / growth & development. Skin Physiological Phenomena

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071661.001).
  • [ISSN] 0171-2004
  • [Journal-full-title] Handbook of experimental pharmacology
  • [ISO-abbreviation] Handb Exp Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents; 0 / Oligonucleotides; 0 / Toll-Like Receptors; 63231-63-0 / RNA; 9007-49-2 / DNA
  • [Number-of-references] 101
  •  go-up   go-down


26. Thomas L, Dalle S: Dermoscopy provides useful information for the management of melanonychia striata. Dermatol Ther; 2007 Jan-Feb;20(1):3-10
MedlinePlus Health Information. consumer health - Nail Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the other hand, the presence of a brown pigmentation overlaid by longitudinal lines irregular in their thickness, spacing, color, or parallelism is highly in favor of a melanoma.
  • Gray homogeneous lines are observed in case of lentigo, lentiginoses, ethnic or drug-induced pigmentations, and in post-traumatic pigmentations.
  • Blood spots are characterized by their round-shaped proximal edge and their filamentous distal edge and are highly suggestive of subungual hemorrhages.
  • Dermoscopic examination of the free edge of the nail plate gives information on the lesion location; pigmentation of the dorsum of the nail plate is in favor of a proximal nail matrix lesion, whereas pigmentation the lower part of the nail edge is in favor of a lesion of the distal matrix.
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans. Melanoma / diagnosis. Melanoma / pathology. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403255.001).
  • [ISSN] 1396-0296
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Number-of-references] 14
  •  go-up   go-down


27. Menichini F, Tundis R, Loizzo MR, Bonesi M, Provenzano E, de Cindio B, Menichini F: In vitro photo-induced cytotoxic activity of Citrus bergamia and C. medica L. cv. Diamante peel essential oils and identified active coumarins. Pharm Biol; 2010 Sep;48(9):1059-65
Hazardous Substances Data Bank. 5-METHOXYPSORALEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The search for innovative therapeutic approaches is gaining more interest in clinical oncology.
  • In order to evaluate the cytotoxic activity two melanoma models, such as amelanotic melanoma C32 and malignant melanoma A375, were used.
  • This phototoxicity may be considered as a treatment option in some cases of lentigo maligna or lentigo maligna melanoma.
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Drug Discovery. Drug Evaluation, Preclinical. Gas Chromatography-Mass Spectrometry. Humans. Inhibitory Concentration 50. Melanoma / drug therapy. Melanoma, Amelanotic / drug therapy. Methoxsalen / analogs & derivatives. Methoxsalen / analysis. Methoxsalen / chemistry. Methoxsalen / pharmacology. Methoxsalen / radiation effects. Photochemotherapy. Phytotherapy. Time Factors. Ultraviolet Rays

  • Hazardous Substances Data Bank. 8-METHOXYPSORALEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20690896.001).
  • [ISSN] 1744-5116
  • [Journal-full-title] Pharmaceutical biology
  • [ISO-abbreviation] Pharm Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Coumarins; 0 / Oils, Volatile; 4FVK84C92X / 5-methoxypsoralen; JWE1QQ247N / 5,7-dimethoxycoumarin; U4VJ29L7BQ / Methoxsalen
  •  go-up   go-down


28. Choi H, Ahn S, Lee BG, Chang I, Hwang JS: Inhibition of skin pigmentation by an extract of Lepidium apetalum and its possible implication in IL-6 mediated signaling. Pigment Cell Res; 2005 Dec;18(6):439-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of effective skin-lightening agents is an increasingly important area of research aimed at the treatment of hyperpigmentation induced by UV irradiation or by medical conditions such as melasma, postinflammatory melanoderma and solar lentigo.
  • Although some inhibit tyrosinase, identifying and understanding the mechanisms of action of other agents is an important goal if more effective pigmentation inhibitors are to be developed.
  • We present here that an extract of Lepidium apetalum (ELA) decreased UV-induced skin pigmentation in brown guinea pigs and melanogenesis of HM3KO human melanoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280009.001).
  • [ISSN] 0893-5785
  • [Journal-full-title] Pigment cell research
  • [ISO-abbreviation] Pigment Cell Res.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Melanins; 0 / Microphthalmia-Associated Transcription Factor; 0 / Plant Extracts; 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


29. Imiquimod for superficial and in situ skin malignancy. Drug Ther Bull; 2009 Oct;47(10):113-6
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 'off-label') have been proposed and practised, including as treatment for pre-cancerous conditions such as Bowen's disease (squamous cell carcinoma in situ) and lentigo maligna (an in situ precursor of melanoma).2,3 Here we review the use of imiquimod for small superficial primary BCC in adults, Bowen's disease and lentigo maligna.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Bowen's Disease / drug therapy. Carcinoma, Basal Cell / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19809085.001).
  • [ISSN] 0012-6543
  • [Journal-full-title] Drug and therapeutics bulletin
  • [ISO-abbreviation] Drug Ther Bull
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 26
  •  go-up   go-down


30. Metcalf S, Crowson AN, Naylor M, Haque R, Cornelison R: Imiquimod as an antiaging agent. J Am Acad Dermatol; 2007 Mar;56(3):422-5
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Topical imiquimod therapy has proven to be effective for a variety of infectious, neoplastic, and inflammatory dermatologic diseases.
  • Several published reports have validated the benefit of imiquimod therapy for actinic keratoses and superficial melanoma and nonmelanoma skin cancers.
  • There is, however, limited evidence demonstrating the use of topical imiquimod application as an antiaging treatment.
  • OBJECTIVES: We examined the effectiveness of imiquimod 5% cream in the treatment of photoaging by evaluating pretreatment and posttreatment biopsy specimens and documenting the histologic changes.
  • METHODS: This study represents an extension of an earlier project in our department in which patients with biopsy-proven lesions of lentigo maligna (LM) were recruited from a university dermatology service, a hospital, and referrals from private practitioners for an open-labeled efficacy trial with daily topical application of 5% imiquimod for 3 months.
  • Biopsy of clinically affected skin was carried out on all patients before and after treatment.
  • CONCLUSION: Topical imiquimod appears to induce reparative changes to the epidermis and the dermal collagen table in chronically sun-damaged skin associated with LM, indicating its potential use as an antiaging treatment.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Hutchinson's Melanotic Freckle / physiopathology. Skin Aging / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology
  • [MeSH-minor] Cell Count. Collagen / metabolism. Dermis / metabolism. Dermis / pathology. Drug Administration Schedule. Epidermis / metabolism. Epidermis / pathology. Humans. Melanins / metabolism. Melanocytes / pathology. Ointments

  • MedlinePlus Health Information. consumer health - Skin Aging.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184874.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Melanins; 0 / Ointments; 9007-34-5 / Collagen; 99011-02-6 / imiquimod
  •  go-up   go-down


31. Somani N, Martinka M, Crawford RI, Dutz JP, Rivers JK: Treatment of atypical nevi with imiquimod 5% cream. Arch Dermatol; 2007 Mar;143(3):379-85
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of atypical nevi with imiquimod 5% cream.
  • BACKGROUND: 5% Imiquimod cream is a topical immune response modifier that has been used off-label to treat malignant melanocytic proliferations such as lentigo maligna.
  • CONCLUSIONS: Twelve weeks of imiquimod treatment failed to cause lesional resolution.
  • Uncertainties remain concerning imiquimod use for chemoprevention of AN, and the posttreatment histologic features may be misinterpreted as severe melanocytic atypia or melanoma.
  • [MeSH-major] Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Nevus / drug therapy

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372103.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Dosage Forms; 99011-02-6 / imiquimod
  •  go-up   go-down


32. Woodmansee CS, McCall MW: Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod. Dermatol Surg; 2009 Aug;35(8):1286-9
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
  • [MeSH-major] Aminoquinolines / adverse effects. Antineoplastic Agents / adverse effects. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19438661.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


33. Chapman MS, Spencer SK, Brennick JB: Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol; 2003 Jul;139(7):943-4
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Facial Neoplasms / drug therapy. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12873902.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


34. Borucki U, Metze D: Topical treatment of lentigo maligna melanoma with imiquimod 5% cream. Dermatology; 2003;207(3):326-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.
  • [MeSH-major] Aminoquinolines / administration & dosage. Hutchinson's Melanotic Freckle / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Facial Neoplasms / drug therapy. Facial Neoplasms / pathology. Female. Follow-Up Studies. Humans. Ointments. Treatment Outcome

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14571081.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Ointments; P1QW714R7M / imiquimod
  •  go-up   go-down


35. Martires KJ, Capaldi L, Pattee SF, Maloney ME, Bordeaux JS: Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production. Arch Dermatol; 2010 Sep;146(9):1047-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production.
  • [MeSH-major] Aminoquinolines / therapeutic use. Hutchinson's Melanotic Freckle / drug therapy. Melanoma, Amelanotic / drug therapy. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Topical. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Nose. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855714.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down






Advertisement